Jagsonpal Pharmaceuticals Limited , a key player in the Indian pharmaceutical sector, has announced its unaudited financial results for the quarter and half year ended September 30, 2025, showcasing a mixed performance.

Financial Highlights

Jagsonpal Pharmaceuticals reported a net profit of 125.74 million rupees for the quarter, marking a 9.73% increase from 114.59 million rupees in the same period last year. This growth in profitability comes despite a marginal 0.30% year-over-year decline in revenue, which stood at 744.65 million rupees compared to 746.92 million rupees in the corresponding quarter of the previous fiscal year.

Operational Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed improvement, rising to 165.00 million rupees from 162.00 million rupees in the year-ago period. This resulted in an EBITDA margin expansion of 46 basis points, reaching 22.15% compared to 21.69% in the same quarter last year.

Corporate Actions

The company's Board of Directors approved these unaudited financial results at a meeting held on November 3, 2025. During the quarter, Jagsonpal Pharmaceuticals granted 272,500 stock options to eligible employees under its Employee Stock Option Plan 2022 and allotted 104,774 equity shares upon exercise of vested stock options.

Dividend Information

Jagsonpal Pharmaceuticals paid a final dividend of Rs. 2.5 per equity share (face value Rs. 2 each), totaling Rs. 166.58 million for the year ended March 31, 2025. This dividend was approved by shareholders at the Annual General Meeting held on September 24, 2025.

Business Overview

The company primarily operates in manufacturing and trading of pharmaceutical products, including active pharmaceutical ingredients, for customers in India and overseas.

Audit Review

The financial results were reviewed by the Audit Committee, and a limited review was conducted by statutory auditors Walker Chandiok & Co LLP.

The company's ability to maintain profitability and improve margins in a challenging revenue environment demonstrates resilience. However, the slight dip in revenue might warrant attention to the company's growth strategies in the coming quarters.

Jagsonpal Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical sector, has announced a significant addition to its leadership team. The company has appointed Mr. Amrut Medhekar as its new Chief Operating Officer (COO), effective September 04, 2025. This strategic move aims to strengthen the company's operational capabilities and drive future growth.

Board Approval and Appointment Process

The appointment of Mr. Medhekar was approved by Jagsonpal Pharmaceuticals' Board of Directors, following a recommendation from the Nomination and Remuneration Committee. This decision underscores the company's commitment to bringing in top-tier talent to enhance its executive leadership.

Amrut Medhekar's Professional Background

Mr. Medhekar brings a wealth of experience to his new role at Jagsonpal Pharmaceuticals:

• Industry Experience: Over 28 years in the pharmaceutical sector
• Expertise: Extensive background in Sales, Marketing, and Business Operations
• Education:
  • MBA in Marketing from Jiwaji University
  • Certificate course in General Management from IIM Ahmedabad

Previous Leadership Roles

Prior to joining Jagsonpal Pharmaceuticals, Mr. Medhekar has held several senior positions in renowned pharmaceutical companies:

• CEO – Business Operations at Akums Drugs & Pharmaceuticals Limited
• Senior leadership roles at:
  • Torrent Pharmaceuticals Ltd
  • Ranbaxy Ltd
  • Zydus Life Sciences Ltd
  • Wockhardt Ltd

These positions have provided Mr. Medhekar with diverse experience in various strategic and operational roles within the pharmaceutical industry.

Implications for Jagsonpal Pharmaceuticals

The appointment of Mr. Medhekar as COO is expected to bring fresh perspectives and strategic insights to Jagsonpal Pharmaceuticals. His extensive experience in sales, marketing, and business operations aligns well with the company's goals for operational excellence and market expansion.

Corporate Governance Note

In line with corporate governance best practices, Jagsonpal Pharmaceuticals has confirmed that Mr. Amrut Medhekar is not related to any Director or Key Managerial Personnel of the company. This appointment has been made purely on the basis of merit and professional expertise.

The addition of Mr. Medhekar to the executive team marks an important step for Jagsonpal Pharmaceuticals as it continues to strengthen its position in the competitive pharmaceutical market. Stakeholders will be keenly watching how this new leadership appointment influences the company's operational strategies and overall performance in the coming years.